Navigation Links
Oxygen Biotherapeutics, Inc. Announces Closing of Offer to Acquire Warrants
Date:7/20/2009

DURHAM, N.C., July 20 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has closed its proposed acquisition of outstanding common stock purchase warrants.

The company acquired and cancelled 52.2 million common stock purchase warrants with an exercise price of $0.247 per share and an additional 18.7 million warrants with an exercise price of $0.245 per share, or a total of 70.9 million warrants. Prior to the transaction there were 121 million warrants outstanding, so the transaction reduces that number to 49.1 million common stock purchase warrants now outstanding. In exchange for the cancelled warrants the company issued to the holders 35.5 million shares of restricted common stock and paid to them $2.8 million in cash.

"The closing of the new financing by the Vatea Fund and the exchange of the warrants marks an enormous leap towards positioning our company for attracting and obtaining future financings that are necessary to support our product development," said Chris Stern, Oxygen Biotherapeutics, Inc. chairman and CEO. "We are glad to have a financing arrangement in place with Vatea Fund that provides the means, after achieving specific milestones, to finance our future growth and development plans. We have significantly improved our working capital position which will enable us to advance the product development programs we have in place and consider a move to a major stock exchange."

The securities purchase agreement with Vatea Fund, assuming all milestones are achieved in a timely manner, provides for Vatea Fund to purchase an additional 60 million shares of the company's stock for a total purchase of 80 million shares for $20 million in cash.

For additional comments by Chris Stern on the investment by Vatea Fund, please see his latest blog and the video posted on the company website at www.oxybiomed.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes and cosmetic applications. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release and the video referenced in this news release, which is posted on the company website, contain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to use of the money received from Vatea Fund and steps to move the company stock listing to a major exchange. Actual events or results may differ from Oxygen Biotherapeutics' expectations. There can be no assurance that the funds received will be sufficient for the company's growth and development plans or that the company will be successful in moving the stock listing to a major exchange. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics' business can be found in the company's public report filings with the Securities and Exchange Commission, which are available on the SEC website at www.sec.gov and through our website at www.oxybiomed.com. Oxygen Biotherapeutics disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Home Oxygen Patients and Family Members Visit Capitol Hill to Ask Congress to Protect Medicare Home Oxygen Therapy Benefit
2. Congressmen Mike Ross and Kendrick Meek Introduce Bill to Protect Medicare Patients Who Require Medical Oxygen Therapy at Home
3. National Advocacy Organization Representing Home Oxygen Patients Praises Introduction of Medicare Home Oxygen Therapy Act
4. Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants
5. Oxygen + MRI might help determine cancer therapy success, researchers find
6. Hummingbird Coaching Partners with Leeza's Place to Help Caregivers “Take Your Oxygen First”
7. Long-term study shows low oxygen levels in prostate tumors can predict recurrence
8. Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With Naval Medical Research Center and Walter Reed Army Institute of Research
9. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel
10. Turtle Island Oxygen Trust Sponsors Free Hyperbaric Treatments
11. G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 18, 2017 , ... “Beyond Our Imaginations: The Infinite God”: shows the importance ... God” is the creation of published author, Mark Lawrence, born in Michigan, the author ... problem with becoming a greater man of God is that I have to be ...
(Date:8/18/2017)... ... ... Mandate for Kingdom Builders”: a call to walk as citizens of the Kingdom and ... published author, John F. McGeorge, Jr. Dr. John F. McGeorge Jr., B.A., J.D., ... three decades training pastors and Christian leaders. He also met his wife, Valerija, ...
(Date:8/18/2017)... ... ... “Case #10-5411 Veterans Administration”: a personal account of corruption ... Administration” is the creation of published author, Carol Mulhern, single mother of two ... work at the Coatesville VAMC as a file clerk then later became the ...
(Date:8/17/2017)... ... 2017 , ... The award-winning producers of the Innovations with ... for Therapeutic Recreation Certification (NCTRC), slated to air nationwide, fourth quarter 2017. Check ... non-profit, international organization dedicated to professional excellence for the protection of consumers through ...
(Date:8/17/2017)... ... 17, 2017 , ... CARF International announced that Inland Detox, ... drug and alcohol detox program. This accreditation decision represents the highest level of ... conformance to the CARF standards. , Behavioral health organizations receiving a Three-Year Accreditation ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... GAITHERSBURG, Md. , Aug. 7, 2017 /PRNewswire/ ... for healthcare member acquisition, retention, and engagement, announced ... Director of Strategy and Product Development, effective as ... strategic consulting and technology implementation strategy for our ... years of experience in consulting and business analytics ...
(Date:8/4/2017)... ROCKVILLE, Md. , Aug. 4, 2017 ... during or shortly after a physician/patient consult has long ... industry, and was a notable focus of the largest ...  This is according to healthcare market research firm Kalorama ... of care testing (POCT) offerings or related supplies and ...
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
Breaking Medicine Technology: